Dr. Basch is a medical oncologist and health services researcher. His clinical expertise is prostate cancer, and his research expertise includes patient-reported outcomes, drug regulatory policy, and comparative effectiveness research. He is also an Associate Editor of the Journal of the American Medical Association (JAMA).
He is a federally appointed member of the Methodology Committee of the Patient-Centered Outcomes Research Institute (PCORI), a member of the Board of Directors of the International Society for Quality of Life Research (ISOQOL), Co-Chair of the Health Outcomes Committee of the Alliance for Clinical Trials in Oncology, and a member of the Board of Scientific Advisors of the National Cancer Institute. He led the National Cancer Institute's initiative to develop a patient-reported adverse event monitoring system for use in clinical research (the “PRO-CTCAE”), and is study chair for multiple trials employing patient-reported endpoints.
Elected to Board of Directors
2019, American Society of Clinical Oncology (ASCO)
Ware/Tarlov Career Achievement Prize in Patient-Reported Outcomes Measures
2017, Health Assessment Labs
Appointee, Board of Scientific Advisors
2012, National Cancer Institute
Board of Directors
2011, International Society for Quality of Life Research